This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
waldenstrom-macroglobulinemia
Waldenström Macroglobulinemia
Waldenström macroglobulinemia is lymphoplasmacytic lymphoma producing IgM monoclonal protein; MYD88 L265P in ~90% drives NF-κB and JAK-STAT3. Hyperviscosity, neuropathy, and cryoglobulinemia are hallmarks; ibrutinib and zanubrutinib are approved for MYD88 L265P WM.
Entry Metadata
| Field | Value |
|---|---|
| ID | waldenstrom-macroglobulinemia |
| Name | Waldenström Macroglobulinemia |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015;373(18):1765-1774. · PubMed 26352686
- Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038-2050. · PubMed 32828187